Health Care·Biotechnology·$4.5B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.20 | N/A | -293.44% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-1.20 | N/A | -293.44% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed a cautious approach in light of current challenges. They emphasized commitment to their research pipeline.
Management did not provide specific guidance for future performance.
The company is focused on ongoing development and research efforts.
The earnings report indicates that Amicus Therapeutics is facing significant challenges, particularly reflected in their EPS miss. The stock reacted negatively, dropping 3.26%, likely due to investor concerns over the lack of guidance and the substantial loss reported. Without clear direction from management, uncertainty may persist in the near term.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
COPART INC
Feb 23, 2016